According to data on neoplasm incidence in the last five year period non-small cell carcinoma is becoming a leading neoplasm in a great number of countries, and also it is important to point out the rise in incidence of non-small cell carcinoma adenocarcinoma in female nonsmokers in their forties. The development in science allows us to understand the origins of this malignant disease even up to the molecular level better and more precise. Nowadays are known many driver mutations connected to non-small cell adenocarcinoma development, among more common ones are mutations in KRAS and EGFR genes, followed by ALK and ROS genes. Detecting those mutations using molecular and immunohistochemical testings, we can predict the outcome and modify the treatment. Another discovery nowadays is “immunological status of tumour“, and one of those factors is PD-L1 molecule, which is also one of the newest predictive markers. It is a ligand that binds to a cell receptor expressed on immuno-cells and supresses their activation. That way, cancer cells can surpass the host's immunological response. From knowledge of this mechanism has risen an efficient immunological therapy. The interest lies within the question of possible connection between certain driver mutation and immunological status via PDL1 expression. So far the research is not consistent with the results about the correlation between the expression of PD-L1 and existance of driver mutations. In this paper we analyse the possible correlation between the PD-L1 status of a patient with a lung adenocarcinoma and presence or absence of mutation in ALK gene.